Liljendahl, Mie Sylow http://orcid.org/0000-0001-7419-7086
Loft, Nikolai
Egeberg, Alexander
Skov, Lone
Nguyen, Tri-Long
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 2 June 2022
Accepted: 10 January 2023
First Online: 7 February 2023
Declarations
:
: According to Danish legislation, no ethics approval is required in register-based studies without direct contact to the participants.
: Not applicable.
: MSL reports no conflict of interest.Dr. Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.Dr. Skov has been an advisor, investigator, and speaker for Abbvie, Eli Lilly, Novartis, Sanofi, Celegene, Leo Pharma, BMS, UCB, Pfizer, and Almirall. LS reports non-financial support from Abbvie, Sanofi, and Janssen and grants from Novartis, Janssen, BMS, and Sanofi.Dr. Loft has been an honorary speaker for Janssen Cilag and Eli Lilly.Dr. Nguyen reports no conflict of interest.